Rödén‐Jüllig 2003.

Study characteristics
Methods	Randomisation: randomisation tables, stratified for gender Concealment: sequentially numbered containers from pharmacy Double blind Exclusions during trials: none Losses to follow‐up: none
Participants	Sweden 441 participants 226 (51%) male 100% CT before entry Ischaemic stroke < 72 hours since stroke onset SSSS ≥ 1 point
Interventions	Treatment: aspirin 325 mg orally once daily Control: placebo Duration: 5 days
Outcomes	Death ≥ 2 points (may be in different items) worsening on SSSS at 5 days Ability to walk unaided Increased need for ADL help at 3 months
Funding source	The trial was supported by grants from the Serafimer Hospital Foundation, the County Council of Stockholm, Department of Research, Development & Education, the Claes Groschinsky Foundation, the Loo and Hans Osterman Foundation, the Eirs 50‐year Foundation, the SALUS 50‐year Foundation, the 1987 Foundation for Stroke Research, the Tore Nilsson Foundation for Medical Research and the Karolinska Institutet Foundations for Research. Miles Inc through Bayer AG provided the placebo tablets free of charge. The aspirin tablets were purchased from Miles Inc. These companies were not involved in the conduct of this trial in any other way.
Notes	Exclusions: specified in protocol – severe concomitant medical conditions or pre‐existing neurological illness, bleeding risk, blood pressure > 240/140 mmHg Follow‐up: 3 months
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Standard randomisation tables used.
Allocation concealment (selection bias)	Low risk	Packages taken in numerical order.
Blinding of participants and personnel (performance bias) all outcomes	Low risk	Participants and personnel blinded.
Blinding of outcome assessment (detection bias) all outcomes	Low risk	No concerns regarding blinding of outcome assessment.
Incomplete outcome data (attrition bias) all outcomes	Low risk	No missing outcome data.
Selective reporting (reporting bias)	Low risk	Study protocol noted.
Other bias	Low risk	No sources of other bias identified.